Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
Kumar, Shant Hand, P H Marsden, Henry B Kumar, Patricia Thor, A
Kumar, Shant
Hand, P H
Marsden, Henry B
Kumar, Patricia
Thor, A
Citations
Altmetric:
Abstract
A monoclonal antibody, RAP-5, raised against the 21,000d ras-oncogene product, p21, was used in an immunoperoxidase staining procedure to study the expression of p21 in normal children's and foetal kidneys, pre-malignant lesions and benign and malignant childhood renal tumours with good, moderate or poor prognosis. ras-p21 was expressed in both normal and foetal kidneys but its distribution in renal tumours differed markedly (p less than 0.01). A quantitative liquid competition radioimmunoassay (RIA) was used to determine ras-p21 level in tissue homogenates. The results were expressed as pg of ras-p21 per microgram protein of tissue extract. There were significant differences in the levels of ras-p21 among various renal tissue extracts (p less than 0.05). Generally it emerged that the amount of ras-p21 was greater in both malignant renal tumours and foetal kidneys compared to normal kidneys, pre-malignant lesions and benign renal tumours.
Description
Date
1991
Publisher
Collections
Keywords
Kidney Cancer
Biological Tumour Markers
Wilms Tumour
Biological Tumour Markers
Wilms Tumour
Type
Article
Citation
Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours., 11 (4):1657-62 Anticancer Res.